Get your patient on Carnitor - Levocarnitine injection, Solution (Levocarnitine)
Carnitor - Levocarnitine injection, Solution prescribing information
INDICATIONS AND USAGE
For the acute and chronic treatment of patients with an inborn error of metabolism which results in secondary carnitine deficiency.
For the prevention and treatment of carnitine deficiency in patients with end stage renal disease who are undergoing dialysis.
DOSAGE AND ADMINISTRATION
CARNITOR ® Injection is administered intravenously.
Metabolic Disorders
The recommended dose is 50 mg/kg given as a slow 2-3 minute bolus injection or by infusion. Often a loading dose is given in patients with severe metabolic crisis, followed by an equivalent dose over the following 24 hours. It should be administered q3h or q4h, and never less than q6h either by infusion or by intravenous injection. All subsequent daily doses are recommended to be in the range of 50 mg/kg or as therapy may require. The highest dose administered has been 300 mg/kg.
It is recommended that a plasma carnitine concentration be obtained prior to beginning this parenteral therapy. Weekly and monthly monitoring is recommended as well. This monitoring should include blood chemistries, vital signs, plasma carnitine concentrations (the plasma free carnitine concentration should be between 35 and 60 µmol/L) and overall clinical condition.
ESRD Patients on Hemodialysis
The recommended starting dose is 10-20 mg/kg dry body weight as a slow 2-3 minute bolus injection into the venous return line after each dialysis session. Initiation of therapy may be prompted by trough (pre-dialysis) plasma levocarnitine concentrations that are below normal (40-50 µmol/L). Dose adjustments should be guided by trough (pre-dialysis) levocarnitine concentrations, and downward dose adjustments (e.g. to 5 mg/kg after dialysis) may be made as early as the third or fourth week of therapy.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
CONTRAINDICATIONS
None known.
ADVERSE REACTIONS
Clinical Trials Experience
Transient nausea and vomiting have been observed. Less frequent adverse reactions are body odor, nausea, and gastritis. An incidence for these reactions is difficult to estimate due to the confounding effects of the underlying pathology.
The table below lists the adverse events that have been reported in two double-blind, placebo-controlled trials in patients on chronic hemodialysis. Events occurring at ≥5% are reported without regard to causality.
Placebo (n=63) | Levocarnitine 10 mg (n=34) | Levocarnitine 20 mg (n=62) | Levocarnitine 40 mg (n=34) | Levocarnitine 10, 20 & 40 mg (n=130) | |
Body as Whole | |||||
Abdominal pain | 17 | 21 | 5 | 6 | 9 |
Accidental injury | 10 | 12 | 8 | 12 | 10 |
Allergic reaction | 5 | 6 | 2 | ||
Asthenia | 8 | 9 | 8 | 12 | 9 |
Back pain | 10 | 9 | 8 | 6 | 8 |
Chest pain | 14 | 6 | 15 | 12 | 12 |
Fever | 5 | 6 | 5 | 12 | 7 |
Flu syndrome | 40 | 15 | 27 | 29 | 25 |
Headache | 16 | 12 | 37 | 3 | 22 |
Infection | 17 | 15 | 10 | 24 | 15 |
Injection site reaction | 59 | 38 | 27 | 38 | 33 |
Pain | 49 | 21 | 32 | 35 | 30 |
Cardiovascular | |||||
Arrhythmia | 5 | 3 | 3 | 2 | |
Atrial fibrillation | 2 | 6 | 2 | ||
Cardiovascular disorder | 6 | 3 | 5 | 6 | 5 |
Electrocardiogram abnormal | 3 | 6 | 2 | ||
Hemorrhage | 6 | 9 | 2 | 3 | 4 |
Hypertension | 14 | 18 | 21 | 21 | 20 |
Hypotension | 19 | 15 | 19 | 3 | 14 |
Palpitations | 3 | 8 | 5 | ||
Tachycardia | 5 | 6 | 5 | 9 | 6 |
Vascular disorder | 2 | 2 | 6 | 2 | |
Digestive | |||||
Anorexia | 3 | 3 | 5 | 6 | 5 |
Constipation | 6 | 3 | 3 | 3 | 3 |
Diarrhea | 19 | 9 | 10 | 35 | 16 |
Dyspepsia | 10 | 9 | 6 | 5 | |
Gastrointestinal disorder | 2 | 3 | 6 | 2 | |
Melena | 3 | 6 | 2 | ||
Nausea | 10 | 9 | 5 | 12 | 8 |
Stomach atony | 5 | ||||
Vomiting | 16 | 9 | 16 | 21 | 15 |
Endocrine System | |||||
Parathyroid disorder | 2 | 6 | 2 | 6 | 4 |
Hemic/Lymphatic | |||||
Anemia | 3 | 3 | 5 | 12 | 6 |
Metabolic/Nutritional | |||||
Hypercalcemia | 3 | 15 | 8 | 6 | 9 |
Hyperkalemia | 6 | 6 | 6 | 6 | 6 |
Hypervolemia | 17 | 3 | 3 | 12 | 5 |
Peripheral edema | 3 | 6 | 5 | 3 | 5 |
Weight decrease | 3 | 3 | 8 | 3 | 5 |
Weight increase | 2 | 3 | 6 | 2 | |
Musculo-Skeletal | |||||
Leg cramps | 13 | 8 | 4 | ||
Myalgia | 6 | ||||
Nervous | |||||
Anxiety | 5 | 2 | 1 | ||
Depression | 3 | 6 | 5 | 6 | 5 |
Dizziness | 11 | 18 | 10 | 15 | 13 |
Drug dependence | 2 | 6 | 2 | ||
Hypertonia | 5 | 3 | 1 | ||
Insomnia | 6 | 3 | 6 | 4 | |
Paresthesia | 3 | 3 | 3 | 12 | 5 |
Vertigo | 6 | 2 | |||
Respiratory | |||||
Bronchitis | 5 | 3 | 3 | ||
Cough increase | 16 | 10 | 18 | 9 | |
Dyspnea | 19 | 3 | 11 | 3 | 7 |
Pharyngitis | 33 | 24 | 27 | 15 | 23 |
Respiratory disorder | 5 | ||||
Rhinitis | 10 | 6 | 11 | 6 | 9 |
Sinusitis | 5 | 2 | 3 | 2 | |
Skin And Appendages | |||||
Pruritus | 13 | 8 | 3 | 5 | |
Rash | 3 | 5 | 3 | 3 | |
Special Senses | |||||
Amblyopia | 2 | 6 | 3 | ||
Eye disorder | 3 | 6 | 3 | 3 | |
Taste perversion | 2 | 9 | 3 | ||
Urogenital | |||||
Urinary tract infect | 6 | 3 | 3 | 2 | |
Kidney failure | 5 | 6 | 6 | 6 | 6 |
Postmarketing Experience
The following adverse reactions have been reported:
Neurologic Reactions : Seizures have been reported to occur in patients, with or without pre-existing seizure activity, receiving either oral or intravenous levocarnitine. In patients with pre-existing seizure activity, an increase in seizure frequency and/or severity has been reported.
Hypersensitivity reactions : Anaphylaxis, laryngeal edema and bronchospasm (see WARNINGS ).
Drug Interactions
Reports of INR increase with the use of warfarin have been observed. It is recommended that INR levels be monitored in patients on warfarin therapy after the initiation of treatment with levocarnitine or after dose adjustments.
DESCRIPTION
CARNITOR ® (levocarnitine) is a carrier molecule in the transport of long-chain fatty acids across the inner mitochondrial membrane.
The chemical name of levocarnitine is 3-carboxy-2( R )-hydroxy-N,N,N-trimethyl-1-propanaminium, inner salt. Levocarnitine is a white crystalline, hygroscopic powder. It is readily soluble in water, hot alcohol, and insoluble in acetone. The specific rotation of levocarnitine is between -29° and -32°. Its chemical structure is:
Empirical Formula: C 7 H 15 NO 3
Molecular Weight: 161.20
CARNITOR ® (levocarnitine) Injection is a sterile aqueous solution containing 1 g of levocarnitine per 5 mL vial. The pH is adjusted to 6.0 - 6.5 with hydrochloric acid or sodium hydroxide.
CLINICAL PHARMACOLOGY
CARNITOR ® (levocarnitine) is a naturally occurring substance required in mammalian energy metabolism. It has been shown to facilitate long-chain fatty acid entry into cellular mitochondria, thereby delivering substrate for oxidation and subsequent energy production. Fatty acids are utilized as an energy substrate in all tissues except the brain. In skeletal and cardiac muscle, fatty acids are the main substrate for energy production.
Primary systemic carnitine deficiency is characterized by low concentrations of levocarnitine in plasma, RBC, and/or tissues. It has not been possible to determine which symptoms are due to carnitine deficiency and which are due to an underlying organic acidemia, as symptoms of both abnormalities may be expected to improve with CARNITOR ® . The literature reports that carnitine can promote the excretion of excess organic or fatty acids in patients with defects in fatty acid metabolism and/or specific organic acidopathies that bioaccumulate acylCoA esters. 1-6
Secondary carnitine deficiency can be a consequence of inborn errors of metabolism or iatrogenic factors such as hemodialysis. CARNITOR ® may alleviate the metabolic abnormalities of patients with inborn errors that result in accumulation of toxic organic acids. Conditions for which this effect has been demonstrated are: glutaric aciduria II, methyl malonic aciduria, propionic acidemia, and medium chain fatty acylCoA dehydrogenase deficiency. 7,8 Autointoxication occurs in these patients due to the accumulation of acylCoA compounds that disrupt intermediary metabolism. The subsequent hydrolysis of the acylCoA compound to its free acid results in acidosis which can be life-threatening. Levocarnitine clears the acylCoA compound by formation of acylcarnitine, which is quickly excreted. Carnitine deficiency is defined biochemically as abnormally low plasma concentrations of free carnitine, less than 20 µmol/L at one week post term and may be associated with low tissue and/or urine concentrations. Further, this condition may be associated with a plasma concentration ratio of acylcarnitine/levocarnitine greater than 0.4 or abnormally elevated concentrations of acylcarnitine in the urine. In premature infants and newborns, secondary deficiency is defined as plasma levocarnitine concentrations below age-related normal concentrations.
End Stage Renal Disease (ESRD) patients on maintenance hemodialysis may have low plasma carnitine concentrations and an increased ratio of acylcarnitine/carnitine because of reduced intake of meat and dairy products, reduced renal synthesis and dialytic losses. Certain clinical conditions common in hemodialysis patients such as malaise, muscle weakness, cardiomyopathy and cardiac arrhythmias may be related to abnormal carnitine metabolism.
Pharmacokinetic and clinical studies with CARNITOR ® have shown that administration of levocarnitine to ESRD patients on hemodialysis results in increased plasma levocarnitine concentrations.
HOW SUPPLIED
CARNITOR ® (levocarnitine) Injection is available in 1 g per 5 mL single dose vials packaged 5 vials per carton (NDC 54482-147-01). CARNITOR ® (levocarnitine) Injection 5 mL vial is distributed by Leadiant Biosciences, Inc.
Store vials at controlled room temperature (25°C). See USP. Discard unused portion of an opened vial, as the formulation does not contain a preservative.
US Patent Nos. 6,335,369; 6,429,230; 6,696,493
Rx only.
